BNGO

MKT CAP:$4M

Bionano Genomics, Inc.

Market Cap

$4M

Healthcare·Medical - Diagnostics & Research·🇺🇸 United States·NASDAQ

Healthcare·Medical·🇺🇸·NASDAQ

Stock Price

$1.21-$0.38 (-23.90%)

Apr 24, 2026

Company Details

Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and fun...

CEO

Robert Erik Holmlin

IPO Date

Aug 21, 2018

Website

www.bionanogenomics.com

Key Metrics TTM

Revenue

$29M

-7.4% YoY

Net Income

-$26M

EPS (Diluted)

-$6.19

Free Cash Flow

-$16M

Revenue / Share

$5.24

Gross Margin

22.0%

Operating Margin

-116.9%

Net Margin

-92.6%

FCF Margin

-57.3%

P/S

0.1x

P/E

—

Earnings Reports

Q1 2026

May 13, 2026

PENDING

FY 2025

Mar 23, 2026

$29MEPS -$4.85

Q4 2025

Mar 23, 2026

$8M-2.6%EPS -$1.46

Q3 2025

Nov 13, 2025

$7M+21.3%EPS -$1.59

Q2 2025

Aug 14, 2025

$7M-13.4%EPS -$1.99

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 21	$6M	$239.0K	-$29M
Q1 22	$6M	$861.0K	-$30M
Q2 22	$7M	$1M	-$32M
Q3 22	$7M	$2M	-$32M
Q4 22	$8M	$2M	-$38M
Q1 23	$7M	$2M	-$38M
Q2 23	$9M	$2M	-$38M
Q4 23	$11M	$2M	-$20M
Q1 24	$9M	$3M	-$31M
Q2 24	$8M	$3M	-$17M
Q3 24	$6M	-$8M	-$44M
Q4 24	$8M	$3M	-$12M
Q1 25	$6M	$3M	-$8M
Q2 25	$7M	$3M	-$8M
Q3 25	$7M	$4M	-$9M
Q4 25	$8M	-$4M	-$9M

Valuation

Quarter	P/S	P/E
Q4 21	51.1x	—
Q1 22	33.2x	—
Q2 22	18.5x	—
Q3 22	20.6x	—
Q4 22	16.8x	—
Q1 23	11.6x	—
Q2 23	7.1x	—
Q4 23	2.7x	—
Q1 24	2.0x	—
Q2 24	1.6x	—
Q3 24	1.5x	—
Q4 24	1.0x	—
Q1 25	0.3x	—
Q2 25	0.3x	—
Q3 25	0.2x	—
Q4 25	0.3x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$32M	-$33M
Q2 22	-$28M	-$29M
Q3 22	-$29M	-$30M
Q4 22	-$35M	-$36M
Q1 23	-$32M	-$33M
Q2 23	-$37M	-$37M
Q3 23	-$26M	-$26M
Q4 23	-$30M	-$31M
Q1 24	-$28M	-$28M
Q2 24	-$22M	-$22M
Q3 24	-$13M	-$13M
Q4 24	-$7M	-$7M
Q1 25	-$3M	-$3M
Q2 25	-$3M	-$3M
Q3 25	-$6M	-$6M
Q4 25	-$4M	-$4M

Capital Expenditures

Quarter	CapEx
Q1 22	$982.0K
Q2 22	$469.0K
Q3 22	$290.0K
Q4 22	$2M
Q1 23	$360.0K
Q2 23	$511.0K
Q3 23	$75.0K
Q4 23	$745.0K
Q1 24	$26.0K
Q2 24	$77.0K
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$0
Q4 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 21	+57.9%	+132.1%
Q1 22	+79.8%	+148.7%
Q2 22	+73.0%	+90.6%
Q3 22	+55.1%	+55.4%
Q4 22	+30.4%	+30.4%
Q1 23	+30.2%	+27.0%
Q2 23	+29.9%	+19.9%
Q4 23	+48.5%	-21.9%
Q1 24	+6.7%	-12.8%
Q2 24	+4.8%	-45.2%
Q3 24	-29.9%	+7.5%
Q4 24	-23.9%	-34.6%
Q1 25	-26.4%	-62.6%
Q2 25	-13.4%	-41.4%
Q3 25	+21.3%	-68.2%
Q4 25	-2.6%	-18.0%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$5M	89.6%
Q2 22	$6M	86.6%
Q3 22	$6M	83.9%
Q4 22	$5M	66.7%
Q1 23	$4M	52.4%
Q2 23	$4M	45.4%
Q3 23	$4M	—
Q4 23	$3M	31.5%
Q1 24	$3M	34.4%
Q2 24	$0	0.0%
Q3 24	$2M	36.3%
Q4 24	$2M	23.7%
Q1 25	$2M	24.6%
Q2 25	$1M	16.0%
Q3 25	$0	0.0%
Q4 25	$926.0K	11.6%

OpEx Breakdown

Quarter	R&D	SG&A
Q4 21	$9M	$20M
Q1 22	$11M	$20M
Q2 22	$12M	$22M
Q3 22	$13M	$21M
Q4 22	$14M	$25M
Q1 23	$14M	$26M
Q2 23	$15M	$26M
Q4 23	$12M	$11M
Q1 24	$10M	$20M
Q2 24	$7M	—
Q3 24	$5M	$9M
Q4 24	$3M	$12M
Q1 25	$2M	$9M
Q2 25	$3M	$8M
Q3 25	$3M	$9M
Q4 25	$3M	$9M

Revenue Segments

Quarter

Revenue by Geography

Quarter	Asia Pacific	Emea	North America	Americas
Q4 21	$2M	$2M	$3M	—
Q1 22	$629.0K	$2M	$3M	—
Q2 22	$1M	$3M	$3M	—
Q3 22	$2M	$2M	$4M	—
Q1 23	$979.0K	$3M	—	$3M
Q2 23	$2M	$3M	—	$4M
Q4 23	$1M	$5M	—	$5M
Q1 24	$946.0K	$3M	—	$5M
Q2 24	$761.0K	$4M	—	$3M
Q3 24	$772.0K	$3M	—	$3M
Q2 25	$579.0K	$3M	—	$3M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$24M	$192M	$216M
Q2 22	$27M	$160M	$187M
Q3 22	$28M	$152M	$180M
Q4 22	$5M	$108M	$113M
Q1 23	$4M	$92M	$96M
Q2 23	$15M	$62M	$77M
Q3 23	$35M	$29M	$64M
Q4 23	$18M	$49M	$67M
Q1 24	$16M	$37M	$53M
Q2 24	$10M	$9M	$19M
Q3 24	$9M	$14M	$23M
Q4 24	$9M	$302.0K	$9M
Q1 25	$4M	$15M	$18M
Q2 25	$4M	$13M	$16M
Q3 25	$3M	$0	$3M
Q4 25	$3M	$10M	$13M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 21	483K	+1.3%	+16246.7%
Q1 22	484K	+0.2%	+7.8%
Q2 22	485K	+0.3%	+2.4%
Q3 22	492K	+1.5%	+3.4%
Q4 22	505K	+2.5%	+4.6%
Q1 23	513K	+1.7%	+6.1%
Q2 23	535K	+4.3%	+10.3%
Q4 23	678K	+26.6%	+37.6%
Q1 24	897K	+32.3%	+77.6%
Q2 24	1M	+28.1%	+123.7%
Q3 24	1M	+27.1%	+172.6%
Q4 24	2M	+30.3%	+180.8%
Q1 25	3M	+41.6%	+200.5%
Q2 25	3M	+27.7%	+199.5%
Q3 25	5M	+55.1%	+265.7%
Q4 25	5M	+2.0%	+186.2%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 21	$21.1K	299
Q1 22	$19.1K	299
Q2 22	$22.3K	299
Q3 22	$24.2K	299
Q4 22	$20.3K	405
Q1 23	$18.3K	405
Q2 23	$21.4K	405
Q4 23	$31.2K	344
Q1 24	$25.5K	344
Q2 24	$22.6K	344
Q3 24	$17.7K	344
Q4 24	$68.0K	120
Q1 25	$53.8K	120
Q2 25	$56.1K	120
Q3 25	$61.4K	120
Q4 25	$66.3K	120

Revenue / Employee